To validate our hypothesis, we focused on triple-negative breast cancer (TNBC), recognized as an immunogenic breast cancer subtype due to its higher mutational burden, percentage of tumor-infiltrating lymphocytes, and PDL1 expression, which ultimately support the application of IT [27]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.